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ABSTRACT 
Coronary Heart Disease (CHD) is the cardiovascular disease due to plaque build-up in the coronary artery, reducing the 
blood flow to the heart. STEMI (ST-segment elevation myocardial infarction) is the CHD due to the ST-segment elevation in 
12 and the cardiac marker elevation as Troponin I. The elevation is due to a blockage in the coronary artery, causing the 
blood perfusion and oxygen supply for the heart to decrease.  
We searched the article on internet search engine, and scientific search engines including Scopus and PubMed and 
collected original articles including Randomized Clinical Trial [RCT], comparative, review article, prospective study, and a 
guideline about therapy pharmacology of STEMI from 1993 to 2019.  The following keywords are used: “Guideline of 
STEMI”, “STEMI” OR “streptokinase” OR “fibrinolytic” OR “Pharmacotherapy of STEMI” OR “PCI”. 
Conclusion: STEMI therapy management is discomfort management and reperfusion therapy. The reperfusion therapy is 
aimed to recover the myocardial blood flow, to heal the heart, and to reduce the mortality level. The primary coronary artery 
reperfusion can be administered with the primary percutaneous coronary intervention (PCI). PCI can open a blockage in the 
coronary artery and has a good effect on the short-term and long-term clinical results. Besides, it reduces the death risk, 
myocardial infarction, or repetitive stroke. Meanwhile, reperfusion using fibrinolytics is conducted when PCI is unavailable. 
Moreover, anticoagulant, antithrombotic, and vasodilators are supporting therapies for STEMI patients to reduce chest pain 
and prevent reinfarction. 
 




Cardiovascular disease is the cause of 801,000 death 
cases in the United States of America (USA) [1]. The 
number continuously increases each year. The Sample 
Registration System (SRS) survey 2014 in Indonesia 
indicated that Coronary Heart Disease (CHD) contributed as 
the second main cause of death in all ages after stroke which 
was 12.9% [2]. Meanwhile, according to the data of Basic 
Health Research 2018, the highest rate of heart disease was 
in the North Kalimantan (2.2%), then Gorontalo, 
Yogyakarta, Jakarta, and Central Sulawesi [3]. 
The cardiovascular disease consists of Coronary Heart 
Disease (CHD), heart failure, ventricular arrhythmia, sudden 
cardiac death, rheumatic heart disease, abdominal artery 
aneurysm, periphery artery disease, and congenital heart 
disease [4]. The cause of CHD is the build-up of plaque in 
the coronary artery. The plaque is composed of fat, 
cholesterol, and calcium deposit built up in the coronary 
artery for years. The plaque thickens, narrowing and 
hardening the coronary artery (atherosclerosis) [5]. 
Atherosclerosis occurs due to chronic inflammation 
triggered by endothelial dysfunction in the blood vessel [6].   
Narrowing due to atherosclerosis plaque can block the 
blood vessel and inhibit the blood flow to the heart. The 
condition is called Acute Coronary Syndrome (ACS) [7]. 
The blockage inhibits the oxygen (O2) supply to the 
myocardium, triggering the heart cell damage [4,8]. ACS 
includes Unstable Angina Pectoris (UAP), non-ST segment 
elevation myocardial infarction (NSTEMI), and ST-segment 
elevation myocardial infarction (STEMI) [4]. 
ACS accompanied by the ST-segment elevation in the 
12-lead electrocardiogram is known as STEMI. The 
symptom is the angina-pectoris-like pain in the left chest. In 
STEMI, the pain is more severe and longer (30 minutes or 
more). However, STEMI may occur without chest pain (20-
25%) [9]. 
STEMI therapy management is to recover the 
myocardial blood flow, to save the heart, and to reduce the 
mortality level. Coronary artery reperfusion can be 
performed with a primary percutaneous coronary 
intervention (PCI) or fibrinolytics [10]. In line with the 
STEMI treatment development, supporting knowledge is 
required to succeed optimum tissue reperfusion. This review 
will discuss the therapies used in STEMI patients. 
 
2. Stemi 
STEMI is the product of prolonged total occlusion in an 
epicardial coronary vessel [11]. It is mainly due to broken 





and eroded atherosclerosis plaque. When a plaque is 
ruptured, intravascular bleeding and thrombus formation will 
occur. The thrombus expands to the lumen and turns to be 
either occlusive or non-occlusive [10]. 
The main symptom of STEMI is shortness of breath, 
nausea, vomiting, and unconsciousness. Similar to angina, 
pain is felt in the chest, throat, arm, epigastrium, or back. 
Nevertheless, the pain is more severe and longer. Most 
patients described it as oppressive pain in the chest [12]. The 
result of the electrocardiogram test indicates the ST-segment 
element in 12-lead and cardiac marker elevation as Troponin 
[9]. 
In STEMI, thrombus, emboli, atherosclerosis, or other 
conditions, which block the coronary artery, declining the 
blood perfusion, causing the oxygen supply for the heart to 
decrease. The formation of thrombus is initiated by the 
aggregation of platelet and fibrin strands which inhibit 
hemoglobin, reducing the oxygen supply. Thrombus build-
up around the plaque will cover the coronary artery 
thoroughly [13]. 
The strategies in STEMI therapy management are to 
quickly recover the potency of full blockage in the coronary 
artery, to cut the ischemic time, and to reduce the infarction 
size [14,15]. The recommended therapy for tissue 
reperfusion is to use the primary percutaneous coronary 
intervention (PCI) or fibrinolytics [10]. Anticoagulant, 
antithrombotic, and vasodilator are the supporting therapies 
for STEMI patients to reduce chest pain and prevent 
reinfarction. 
 
3. Management Therapy  
a. Discomfort Management  
To manage the discomfort due to chest pain, we can use 
nitrate. Glyceryl trinitrate sublingual (GTN) of 300-500 μg is 
the first aid in an unstable angina condition or infarction-
potential condition. Intravenous nitrate (GTN 0.6-1.2 
mg/hour or isosorbide dinitrate 1-2 mg/hour) is effective to 
solve a failure in the left ventricle and reduce the repetitive 
or persistent ischemic pain [12]. Nitroglycerin sublingual is 
safe for most STEMI patients. It can increase the myocardial 
oxygen supply and widen the coronary vessel connected to 
infarction, hence reducing preload the needs of myocardial 
oxygen [15] 
However, we must not perform a therapy using nitrate in 
patients with low systolic arterial pressure (<90 mmHg) or 
when the clinical symptoms of RV infarction appear 
(inferior infarction in the electrocardiogram, elevated jugular 
venous pressure, and hypotension). Nitrate must not be 
administered to patients who have used phosphodiesterase-5 
inhibitor for erection dysfunction in the 24 hours prior as it 
can worsen the effect of nitrate hypotension. Meanwhile, the 
nitrate hypotension can be immediately reduced by the 
administration of intravenous atropine [15]. 
Besides nitrate, intravenous β-blocker; such as atenolol 
5-10 is allowable to reduce the pain by reducing the needs of 
myocardial O2 and reducing the short-term mortality and 
arrhythmia in patients after 12 hours of the symptom onset. 
It reduces the risk of the occurrence of ventricle fibrillation 
and reinfarction. However, it must not be administered to 
patients with heart failure and pulmonary edema, 
hypotension (systolic blood pressure < 105 mmHg) and 
bradycardia (heart pulse < 65/second) [12]. An oral β-
blocker therapy should begin in the first 24 hours in patients 
with no contraindication [15]. The dihydropyridine calcium 
channel blockers (such as nifedipine or amlodipine) can be 
added if the patients feel persistent chest pain [12] 
Morphine is an effective analgesic to reduce STEMI 
pain. The Cardiology Guideline in Europe and the USA 
recommends the use of morphine in ACS due to its analgesic 
effect. It reduces the sympathetic effect in the arteriolar and 
venous contraction, producing venous pooling which can 
reduce the cardiac output and arterial pressure [15]. 
However, some meta-analysis research concludes that 
morphine can reduce the antiplatelet effect of clopidogrel in 
the early onset of ACS symptoms, inhibiting the clopidogrel 
therapy effect [16].  
 
b. Reperfusion Therapy 
Reperfusion aims to fix the myocardial blood flow, 
saving myocardium, maintaining the function of the left 
ventricle, and reducing the mortality level. A successful 
reperfusion therapy greatly relies on the period passing 
between the symptom appearance and the therapy. Early 
reperfusion with a short period between “symptom-to-
needle” and “door-to-needle” in patients with myocardial 























Figure 1 Reperfusion Therapy Strategy [15] 






The reperfusion therapy recommended by the American 
Heart Association (AHA) and Perhimpunan Dokter Spesialis 
Kardiovaskuler Indonesia (PERKI) is the percutaneous 
coronary intervention (PCI) and fibrinolytics [14,18]. If the 
patients are positive STEMI based on the result of the 
electrocardiogram test, PCI should be conducted if the 
symptoms appear for ≤ 120 seconds. If they appear for > 120 
seconds, the “door-to-needle” reperfusion strategy using 
fibrinolytics should be used. The reperfusion criteria should 
be checked 60-90 minutes after the fibrinolytics 
administration (Figure 1) [15] The key factor in STEMI 
treatment is the ischemic time, or when the symptoms appear 
until the reperfusion therapy. The longer the artery is 
exposed to occlusion, the wider the ischemic wave which 
extends from endocardium to epicardium so an immediate 
reperfusion act must be made [19] 
 
1) PCI (Percutaneous Coronary Intervention) 
Primary PCI is the reperfusion strategy recommended 
for STEMI patients applied within 12 hours of the symptom 
onset and 120 minutes of STEMI diagnosis. Research 
suggests evidence that the mortality rate is lower in patients 
who take the primary PCI. An immediate primary PCI will 
result in a lower mortality rate [20]. 
Primary PCI gives advantages to patients demonstrating 
contraindication to fibrinolytic therapy. The combination of 
primary PCI, glycoprotein IIb/IIIa receptor antagonist, and 
intracoronary stent implantation will give the best result 
[15]. Besides, it is more effective than fibrinolytics in 
opening a blockage in the coronary artery. Also, it has a 
good effect on the clinical result, either in the short or long 
term and can minimize the death risk, myocardial infarction, 
or repetitive stroke [16]. 
Primary PCI is more recommended for undoubted 
diagnosis than fibrinolytics. It is allowable for patients with 
cardiogenic shock, elevated bleeding risk, and 2-3 hours of 
the symptom onset. It is recommended when plaque is very 
mature and almost impossible to be lysed by fibrinolytics 
[12].  Nevertheless, the PCI implementation is limited as the 
health workers implementing must acquire special skills, not 
to mention it is very expensive. As a result, PCI is only 
available in few hospitals [15].   
 
2) Fibrinolytic Therapy 
Fibrinolytic therapy is the required reperfusion strategy 
in STEMI therapy when primary PCI cannot be punctually 
conducted. Fibrinolytic administration can prevent 30 early 
deaths per 1000 patients treated within six hours after the 
symptom onset. The therapy should be given in 12 hours of 
symptom onset if primary PCI is unlikely to be conducted 
within 120 minutes of STEMI diagnosis and when there is 
no contraindication. It is ideally given within 30 minutes 
after the symptom onset [14]. 
The goal of the therapy is a quick recovery from the 
potential of a fully blocked coronary artery. The use of 
fibrinolytics is proven effective to reduce the mortality rate 
by 25-50%. The highest effectiveness will be acquired if 
fibrinolytics are administered less than 2 hours after the 
symptom onset [14,15]. However, the effectiveness declines 
if fibrinolytics are given to patients with more than 12 hours 
of symptom onset. Within those hours, the plaque has been 
formed and mature, making it difficult to be lysed [12]. 
According to Global Utilisation of Streptokinase and T-
PA for Occluded coronary arteries-1 (GUSTO-1), the 
success rate of fibrinolytics is 50-60% (20). Other research 
conveys that the success rate is 59% [22]. Furthermore, the 
meta-analysis research explains that fibrinolytics can decline 
the mortality rate [23]. 
Fibrinolytics are divided into a non-fibrin-specific agent 
and fibrin-specific agent. The non-fibrin-specific agents are 
streptokinase and urokinase; while the specific ones are 
alteplase, tenecteplase, and reteplase [17,24]. The 
fibrinolytics recommended for STEMI by PERKI are 
streptokinase, alteplase, and tenecteplase [18]. 
Streptokinase is a non-fibrin-specific agent belonging to 
the streptococcus group which is β-hemolytic group-C 
streptococci. Streptokinase combines with circulated 
plasminogen to form an activator complex which produces 
plasmin and breaks thrombus [24,25]. The dose of 
streptokinase infused is 1.5 million IU in 100 mL of saline 
solution for 30-60 minutes [18]. 
Alteplase is a natural enzyme (specific plasminogen) 
produced with recombinant DNA technology using human 
tissue culture. Alteplase is “clot selective”. With fibrin, it 
can form a bind in the clot surface and activate plasminogen 
bound to fibrin. Plasmin is formed from the plasminogen in 
which the fibrin molecule breaks into plasmin and soluble 
clumps. The initial dose of alteplase recommended by 
PERKI is 15 mg in a bolus. A slow intravenous infusion is 
subsequently given with the dose of 0.75 mg/KgBB (max. 
50 mg) for 30 minutes and 0.5 mg/KgBB (max. 35 mg) for 
60 minutes. The dosage regimentation is due to a very brief 
half-life of alteplase. A systemic anticoagulant is given 
before alteplase to manage reocclusion [18,24]. 
Fibrinolytics gives a good advantage with an evidence-
A level if given to patients with 30 minutes of symptom 
onset. However, it demonstrates a side effect which is 
bleeding. Several conditions are contradicted to fibrinolytics; 
such as hemorrhagic stroke, ischemic stroke within the last 
six months, operative trauma or severe head trauma in the 
last three months, and gastrointestinal bleeding in the last 
one month. The conditions are because fibrinolytics can 
increase bleeding risk [18].   
 
c. Other Therapies 
These therapies are therapies used to support 
reperfusion therapy and to maintain the condition of a blood 
vessel after the reperfusion therapy [9]. 






1) Antithrombotic Agent  
 The first goal of antiplatelet and anti-thrombin agent 
treatment is to build and strengthen the condition of the 
artery after reperfusion therapy. The second goal is to reduce 
the potential of thrombus or thrombosis formation in the 
vein. Aspirin, a standard antiplatelet agent for STEMI 
patients, indicates the use of therapy based on Antiplatelet 
Trialists. Aspirin reduces the mortality rate by 27%. P2Y12 
ADP receptor antagonist prevents thrombocyte aggregation 
and activation. P2Y12 inhibitors; such as clopidogrel given 
to patients taking the fibrinolytic therapy are proven 
effective to prevent infarct artery reocclusion in patients with 
successful reperfusion therapy. Glycoprotein IIb/IIIa 
inhibitor is used to prevent thrombotic complications in 
STEMI patients taking PCI [26]. Clopidogrel in aspirin is in 
the evidence A level  [18]. 
The standard anti-thrombin agent used is unfractionated 
heparin (UFH). When the agent is added to aspirin therapy 
and non-fibrin specific fibrinolytic agents; such as 
streptokinase, it declines the mortality rate. Intravenous UFH 
helps maintain the artery condition after reperfusion when 
given to the aspirin regimen and relatively fibrin-specific 
fibrinolytic agents (tPA, rPA, or TNK). The initial UFH dose 
recommended in bolus is 60 U/kg (max. 4,000 U). After the 
dosage, UFH of 12 U/kg is hourly infused (max. 1000 
U/hour). Besides UFH, other anticoagulants which can be 
used are low-molecular-weight heparin (LMWH), 
fondaparinux, or bivalirudin. LMWH is more effective due 
to its higher bioavailability since it is administered 
subcutantly and greater anti-Xa:IIa activity [18].  
Enoxaparin can more significantly reduce the composite 
endpoint of non-fatal reinfarction/death and urgent 
revascularization than UFH in STEMI patients taking 
fibrinolytics. Despite its highly potential bleeding effect, 
enoxaparin is more effective and safer than UFH. In patients 
with anterior infarction location, severe left ventricular 
dysfunction, heart failure, embolism history, mural thrombus 
based on the 2-dimensional electrocardiogram result, or 
atrial fibrillation, the elevation of lung or systemic 
thromboembolism risks can happen. If the condition occurs, 
patients can be given an anti-thrombin therapy (LMWH or 
UFH) followed with warfarin therapy when being treated at 
a hospital for at least three months [26]. 
 
2) β-blocker 
The use of β-blocker in STEMI patients gives an 
advantage in an acute administration and as the secondary 
prevention after infarction. Intravenous β-blocker can repair 
the needs of myocardial oxygen, reduce pain, reduce the 
infarction size, and reduce the ventricular arrhythmia. In 
patients taking fibrinolytics, β-blocker does not reduce the 
mortality rate but reduces the repetitive ischemic incident 
and reinfarction. In conclusion, β-blocker is indeed useful 
for STEMI patients but is not for the contradicted [26]. 
 
3) Inhibition of the Renin-angiotensin Aldosterone 
System  
Inhibitor angiotensin-converting enzyme (ACEI) can 
reduce the mortality rate after STEMI and is more effective 
when used with aspirin and β-blocker. The effectiveness is 
more obvious in patients with a high risk. Short-term use of 
ACE inhibitor is not selective for all STEMI patients with 
stable hemodynamics; such as patients with a systolic blood 
pressure >100 mmHg. It is due to the reduction of 
ventricular remodeling after infarction with the reduction of 
congestive heart failure risk. The risk of repetitive infarction 
is lower in patients taking ACE inhibitors after infarction 
[26]. 
Angiotensin receptor blockers (ARBs) should be given 
to STEMI patients who are intolerant-ACE inhibitor and 
shows clinical signs or has a radiographic diagnosis of heart 
failure. The long-term aldosterone blockage must be 
prescribed for STEMI patients without significant kidney 
dysfunction in which the creatinine level is ≥2.5 mg/dL in 
males and ≥2.0 mg/dL in females. ARBs can be 
administered to hyperkalemic patients (potassium level ≥5.0 
mEq/L) who have taken an ACE-inhibitor therapy, patients 
with left ventricular ejection fraction ≤40%, and patients 
with heart failure or diabetes mellitus. Multidrug regimen to 
inhibit the aldosterone renin-angiotensin system is proven 
effective to reduce cardiovascular mortality and sudden heart 
failure after STEMI. Nevertheless, a thorough exploration of 
it is not yet conducted [26]. 
 
4) Nitrate  
The advantageous effect of nitroglycerin in the 
ventricular remodeling and ischemic process causes 
intravenous nitroglycerin is frequently used with the initial 
dose and until 200 µg/minute when the hemodynamic 
stability can be managed for the first 24-48 hours after 
infarction. However, the use of regular intravenous 
nitroglycerin is less effective than a beta-adrenoceptor dan 
ACE inhibitor. Some uses of nitroglycerin (glyceryl trinitrate 
or GTN) are direct vasodilatation from the coronary artery in 
the area with plaque, venous dilatation, reducing preload. 
Vasodilation with afterload reduction can reduce the needs 
of myocardial oxygen [27].   
Nitroglycerin is for constant pain and as a vasodilator in 
patients with infarction related to the left ventricular disorder 
or hypertension. Nitrate is reportedly useful as in STEMI; 
there may be reduced ventricular filling pressure, wall 
tension, heart performance. Besides, it has an antiplatelet 
effect. Meanwhile, a long-term/regular nitrate is proven 
ineffective for STEMI patients, so nitrate is recommended to 
be given within the first 48 hours [28].  
 
4. Conclusion 
In the therapy management for STEMI patients, the 
therapy mainly recommended by AHA and PERKI is the 





reperfusion therapy which is PCI. However, when PCI is 
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